Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)

ABSTRACT

Compounds of formula I are provided: 
                         
wherein:
 
     R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor (PAI-1) and as therapeutic composition for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis, coronary heart disease and pulmonary fibrosis.

This application claims priority from provisional application Ser. No.60/432,329 filed on Dec. 10, 2002, the entire disclosure of which ishereby incorporated by reference.

This invention relates to aryl, aryloxy, and alkyloxy substitutedindol-3-yl glyoxylic acid derivatives which are useful as inhibitors ofplasminogen activator inhibitor-1 (PAI-1) and as therapeuticcompositions for treating conditions resulting from fibrinolyticdisorders such as deep vein thrombosis and coronary heart disease, andpulmonary fibrosis.

BACKGROUND OF INVENTION

Plasminogen activator inhibitor-1 (PAI-1) is a major regulatorycomponent of the plasminogen-plasmin system. PAI-1 is the principalphysiologic inhibitor of both tissue type plasminogen activator (tPA)and urokinase type plasminogen activator (uPA). Elevated plasma levelsof PAI-1 have been associated with thrombotic events as indicated byanimal experiments (Krishnamurti, Blood, 69, 798 (1987); Reilly,Arteriosclerosis and Thrombosis, 11, 1276 (1991); Carmeliet, Journal ofClinical Investigation, 92, 2756 (1993)) and clinical studies (Rocha,Fibrinolysis, 8, 294, 1994; Aznar, Haemostasis 24, 243 (1994)). Antibodyneutralization of PAI-1 activity resulted in promotion of endogenousthrombolysis and reperfusion (Biemond, Circulation, 91, 1175 (1995);Levi, Circulation 85, 305, (1992)). Elevated levels of PAI-1 have alsobeen implicated in diseases of women such as polycystic ovary syndrome(Nordt, Journal of clinical Endocrinology and Metabolism, 85, 4, 1563(2000)) and bone loss induced by estrogen deficiency (Daci, Journal ofBone and Mineral Research, 15, 8, 1510 (2000)). Accordingly, agents thatinhibit PAI-1 would be of utility in treating conditions originatingfrom fibrinolytic disorder such as deep vein thrombosis, coronary heartdisease, pulmonary fibrosis, Alzheimer's disease, polycystic ovarysyndrome, etc.

WO 99/43654 and WO 99/43651 disclose indole derivatives of formula I asinhibitors phospholipase enzymes useful in preventing inflammatoryconditions.

WO 96/32379 discloses PDE-inhibitor compounds of formula I

-   -   where: R₁ is a hydrogen, halogen, nitro, carboxy, protected        carboxy, acyl, cyano, hydroxyimino, lower alkenyl, optionally        substituted with oxo, or lower alkyl, optionally substituted        with protected carboxy, carboxy, or hydrogen,    -   R₂ is a hydrogen, halogen, carboxy, lower alkenyl, or acyl or        lower alkyl optionally substituted with protected carboxy,        carboxy, lower alkoxy or hydroxy,    -   R₃ is a lower alkenyl, or lower alkenyl, both optionally        substituted with one or more substituents from the group        consisting of oxo, aryl, and a heterocyclic group, and    -   R₄ is carboxy, protected carboxy, or acyl, cyano, halogen, a        heterocyclic group, amino, or lower alkyl

EP 0 655 439 relates to 5,6 fused ring bicyclic compounds correspondingformula I as platelet aggregation inhibitors.

This patent describes 5,6-fused bicyclic ring compounds having both anacidic group “A” linked to the five membered ring by a linking group anda basic group “B” linked to the six membered ring by a linking group.

WO 9748697 relates to substituted azabicyclic compounds includingindoles, 2,3-dihydro-1H-indoles, and benzimidazoles of formula (I) forthe treatment of conditions ameliorated by the administration of aninhibitor of tumor necrosis factor.

wherein:

-   -   A is a five-membered aza heterocycle;    -   B is a six membered aza heterocycle or an optionally substituted        benzene ring;    -   Z is a bond, O, S, NH;    -   A₁ is a bond, C₁–C₆ alkyl, C₂–C₆ alkenyl, or C₂–C₆ alkynyl;    -   R₁ is hydrogen or C₁–C₄ alkyl optionally substituted with OH or        one or more halo; and    -   R₃ is carboxamide, acyl, substituted alkenyl, substituted alkyl,        acylamino, oximino, alkynyl, ketomethyl, aminoalkyl,        sulfonylmethyl, sulfinylmethyl, CF₂OR, alkylamino, alkoxy,        alkylsulfanyl, sulfinyl, acyloxy, sulfonyl, OCF₂R, azo,        aminosulfonyl, sulfonylamino or aminooxalyl

DE 4338770 relates to indole carboxylic acid or tetrazole derivatives offormula (I) useful as phospholipase A2 inhibitors.

wherein:

-   -   Q is CO, CH₂, or CHNHCOR,    -   R₁ is XH, Ar, or XAr;    -   X, Y, Z is 1–19C alkyl, 2–19C alkenyl, 2–19C alkynyl optionally        substituted by an O atom;    -   R₂ is COOH, YCOOH, tetrazolyl, or Y-tetrazolyl; and    -   R₃ is H, ZH, Ar, ZAr, ZOR, ZSR, ZNHR

SUMMARY OF THE INVENTION

This invention relates to compounds of the formula I:

wherein:

-   R₁ is: a) the moiety:

-   -   or    -   b) C₁–C₈ alkyl, benzo[1,3]dioxo-5ylmethyl, cycloalkylalkyl where        the alkyl chain is C₁–C₃ heteroarylalkyl where the alkyl chain        is C₁–C₃, arylalkyl where the alkyl chain is C₁–C₃, preferably        selected from benzyl, CH₂-1-naphthyl, CH₂-2-naphthyl,        CH₂CH₂-phenyl, or CH₂CH₂-naphthyl, wherein the alkyl,        cycloalkyl, heteroaryl, phenyl, benzyl, and napthyl, groups may        be optionally substituted by from 1 to 3 groups selected from        halogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃ perfluoroalkyl,        C₁–C₃ alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio, C₁–C₃        perfluoroalkylthio, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —C(O)NH₂,        —S(O)₂—CH₃, —OH, —NH₂, or —NO₂;

R₄ is hydrogen, halogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃perfluoroalkyl, C₁–C₃ alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio,C₁–C₃ perfluoroalkylthio, —OCHF₂,

-   —CN, —COOH, —CH₂CO₂H, —C(O)CH₃, —CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH,    —NH₂, or —NO₂;

X is O, S, or NH;

R₅ is C₁–C₈ alkyl, C₁–C₃ perfluoroalkyl, C₃–C₆ cycloalkyl, —CH₂—C₃–C₆cycloalkyl, heteroaryl, —CH₂-heteroaryl, phenyl, or arylalkyl where thealkyl chain is C₁–C₈, wherein the rings of the cycloalkyl, heteroaryl,phenyl, and aryl groups may be optionally substituted by from 1 to 5groups selected from halogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃perfluoroalkyl, C₁–C₃ alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio,C₁–C₃ perfluoroalkylthio, —OCHF₂, —CN, —COOH, —CH₂CO₂H, —C(O)CH₃,—CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂;

R₂ is hydrogen, C₁–C₆ alkyl, —CH₂—C₃–C₆ cycloalkyl, or C₁–C₃perfluoroalkyl, wherein the alkyl and cycloalkyl groups may beoptionally substituted by halogen, —CN, C₁–C₆ alkoxy, —COOH, —CH₂CO₂H,—C(O)CH₃, —CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂;

R₃ is: (a) hydrogen, halogen, C₁–C₈ alkyl, C₁–C₈ alkenyl, C₁–C₈ alkynyl,C₃–C₆ cycloalkyl, —CH₂—C₃–C₆ cycloalkyl, heteroaryl, or phenyl, whereinthe alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and phenyl groupsmay be optionally substituted by from 1 to 3 groups selected fromhalogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃ perfluoroalkyl, C₁–C₃alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio, C₁–C₃perfluoroalkylthio, —OCHF₂, —CN, —COOH, —CH₂CO₂H, —C(O)CH₃, —CO₂R₇,—C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂;

or (b) the moiety X—R₆;

R₆ is C₁–C₈ alkyl, C₁–C₈ alkenyl, C₁–C₈ alkynyl, C₃–C₆ cycloalkyl,—CH₂—C₃–C₆ cycloalkyl, heteroaryl, phenyl, aryl-alkyl where the alkylchain is C₁–C₈, CH₂CH₂-phenyl, or CH₂CH₂-napthyl, wherein the alkyl,alkenyl, alkynyl, cycloalkyl, heteroaryl, phenyl, and napthyl groups maybe optionally substituted by from 1 to 3 groups selected from halogen,C₁–C₃ alkyl, C₁–C₃ perfluoroalkyl, preferably —CF₃, —O—C₁–C₃perfluoroalkyl, preferably —OCF₃, —S—C₁–C₃ perfluoroalkyl, preferably—SCF₃, C₁–C₃ alkoxy, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —S(O)₂CH₃, —OH,—NH₂, or —NO₂; and

R₇ is C₁–C₆ alkyl, C₃–C₆ cycloalkyl, —CH₂—C₃–C₆ cycloalkyl, oraryl-alkyl where the alkyl chain is C₁–C₈;

or a pharmaceutically acceptable salt or ester form thereof.

Preferred compounds of this invention are those of formulas (II) and(III):

wherein:

R₁ is C₁–C₈ alkyl, benzo[1,3]dioxo-5yl-methyl, cycloalkylalkyl where thealkyl chain is C₁–C₃ heteroarylalkyl where the alkyl chain is C₁–C₃,arylalkyl where the alkyl chain is C₁–C₃ preferably selected frombenzyl, CH₂-1-naphthyl, CH₂-2-naphyl, CH—₂CH₂-phenyl, orCH₂CH₂-naphthyl, wherein the alkyl, cycloalkyl, heteroaryl, and arylgroups may be optionally substituted by from 1 to 3 groups selected fromhalogen, C₁–C₃ alkyl, C₁–C₃ perfluoroalkyl, —O—C₁–C₃ perfluoroalkyl,—S—C₁–C₃ perfluoroalkyl, C₁–C₃ alkoxy, —OCHF₂, —CN, —COOH, —CH₂CO₂H,—C(O)CH₃, —CO₂R₇, —C(O)NH₂, —S(O)—₂CH₃, —OH, —NH₂, or —NO₂;

R₄ is hydrogen, halogen, C₁–C₆ alkyl, C₁–C₃ haloalkyl, C₁–C₃perfluoroalkyl, —O—C₁–C₃ perfluoroalkyl, —S—C₁–C₃ perfluoroalkyl, C₁–C₃alkoxy, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —S(O)₂CH₃, —OH, —NH₂, or —NO₂;

R₅ is C₁–C₈ alkyl, C₁–C₃ perfluoroalkyl, —CH₂—C₃–C₆ cycloalkyl,—CH₂-heteroaryl, or aryl-alkyl where the alkyl chain is C₁–C₃, whereinthe rings of the cycloalkyl, heteroaryl, and aryl groups may beoptionally substituted by from 1 to 5 groups selected from halogen,C₁–C₃ alkyl, C₁–C₃ perfluoroalkyl, —O—C₁–C₃ perfluoroalkyl, —S—C1–C3perfluoroalkyl, C₁–C₃ alkoxy, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —S(O)₂CH₃,—OH, —NH₂, or —NO₂;

R₂ is hydrogen, C₁–C₆ alkyl, or C₁–C₃ perfluoroalkyl, wherein the alkylgroup may be optionally substituted by halogen, —CN, C₁–C₆ alkoxy,—COOH, —CH₂CO₂H, —C(O)CH₃, —CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or—NO₂;

R₃ is hydrogen, halogen, C₁–C₈ alkyl, C₁–C₈ alkenyl, C₁–C₈ alkynyl,C₃–C₆ cycloalkyl, —CH₂—C₃–C₆ cycloalkyl, heteroaryl, or phenyl, whereinthe alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and phenyl groupsmay be optionally substituted by from 1 to 3 groups selected fromhalogen, C₁–C₃ alkyl, C₁–C₃ perfluoroalkyl, preferably —CF₃, —O—C₁–C₃perfluoroalkyl, preferably —OCF₃, —S—C₁–C₃ perfluoroalkyl, preferably—SCF₃, C₁–C₃ alkoxy, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —S(O)₂CH₃, —OH,—NH₂, or —NO₂;

R₆ is C₁–C₈ alkyl, C₁–C₈ alkenyl, C₁–C₈ alkynyl, C₃–C₆ cycloalkyl,—CH₂—C₃–C₆ cycloalkyl, heteroaryl, phenyl, aryl-alkyl where the alkylchain is C₁–C₈, CH₂CH₂-phenyl, or CH₂CH₂-naphthyl, wherein the alkyl,alkenyl, alkynyl, cycloalkyl, heteroaryl, phenyl, and naphthyl groupsmay be optionally substituted by from 1 to 3 groups selected fromhalogen, C₁–C₃ alkyl, C₁–C₃ perfluoroalkyl, preferably —CF₃, —O—C₁–C₃perfluoroalkyl, preferably —OCF₃, —S—C₁–C₃ perfluoroalkyl, preferably—SCF₃, C₁–C₃ alkoxy, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —S(O)₂CH₃, —OH,—NH₂, or —NO₂; and

R₇ is C₁–C₆ alkyl, C₃–C₆ cycloalkyl, —CH₂—C₃–C₆ cycloalkyl, or C₁–C₈aryl-alkyl where the alkyl chain is C₁–C₈;

or a pharmaceutically acceptable salt or ester form thereof.

Specific examples of compounds according to this invention include:

(1-{4-[(4-Cyanobenzyl)oxy]phenyl}-1-H-indol-3-yl)(oxo)acetic acid;

{1-{4-(3-Methoxybenzyloxy)-phenyl}1H-indol-3-yl}-oxo-acetic acid;

{1-(4-(3-Chlorobenzyloxy)-phenyl]1-H-indol-3-yl}-oxo acetic acid;

{1-{4-(4-Cyanobenzyloxy)-phenyl]-5-fluoro-1H-indol-3-yl}-oxo aceticacid;

{1-{4-(3,5-Dimethoxybenzyloxy)-phenyl]-5-fluoro-1H-indol-3-yl}-oxoacetic acid;

{1-[4-(3-Chlorobenzyloxy)-phenyl]-5-methyl-1H-indol-3yl}-oxo aceticacid;

{1-[4-(4-tert Butylbenzyloxy)-phenyl]-5-methyl-1H-indol-3-yl}-oxo aceticacid;

{1-[4-(2,4-Dichlorobenzyloxy)-phenyl]-5-methyl-1H-indol-3yl}-oxo aceticacid;

{5-Chloro-1-[3-(4-cyanobenzyloxy)-phenyl]-1H-indol-3yl}-oxo acetic acid;

{5-Chloro-1-[3-(3,5-dimethoxybenzyloxy)-phenyl]-1H-indol-3yl}-oxo aceticacid;

{1-[4-(2,3,5,6-tetrafluoro-4-trifluoromethylbenzyloxy)-phenyl]1H-indol-3yl]-oxoacetic acid;

{1-[4-(4-[1,2,3]thiadiazol-4-yl benzyloxy)-phenyl]-1H indol-3yl}-oxoacetic acid;

{1-[4-(2,6,-Dichloropyridin-4-yl methoxy)-phenyl]1H-indol-3yl}-oxoacetic acid;

5-[4-(5-Fluoro-3-carboxy(oxo)methyl-1H-indol-1-yl)phenoxymethyl]-furan-2carboxylic acid ethyl ester;

{1-[4-(2,6,-Dichloropyridin-4-ylmethoxy)-phenyl]-5-methyl-1H-indol-3yl}-oxo acetic acid;

{5-Chloro-1-[3-(2,3,5,6-tetrafluoro-4-trifluromethyl-benzyloxy)-phenyl]-1H-indol-3-yl}-oxoacetic acid;

5-[3-(5-Chloro-3-carboxy(oxo)methyl-1H-indol-1-yl)phenoxymethyl]furan-2-carboxylic acid ethyl ester;

{5-Chloro-1-[3-(4-[1,2,3]thiadiazol-4-yl benzyloxy)-phenyl]-1Hindol-3yl}-oxo acetic acid;

{5-Chloro-1-[3-(2,6-dichloropyridin-4-ylmethoxy)-phenyl]1H-indol-3yl}-oxo acetic acid;

[1,5-Bis-(4-trifluoromethoxy-phenyl)-1H-indol-3-yl]-oxo-acetic acid;

{1-(4-Fluorobenzyl)-5-{2-(4-fluorophenyl)ethoxy}-1H-indol-3-yl}(oxo)aceticacid;

(1-Benzyl-5-benzyloxy-1H-indol-3-yl)-oxo-acetic acid;

{1-Benzyl-5-(2-chloro-4-trifluoromethylphenoxy)-1H-indol-3yl](oxo)aceticacid;

(5-Allyloxy-1-cyclobutylmethyl-1H-indol-3-yl)-oxo-acetic acid;

(5-Allyloxy-1-phenethyl-1H-indol-3-yl)-oxo-acetic acid;

(5-Allyloxy-1-benzo[1,3]dioxol-5-ylmethyl-1H-indol-3-yl)-oxo-aceticacid;

{5-Allyloxy-1-[2-(4-methoxyphenyl)-ethyl]-1H-indol-3-yl}-oxo-aceticacid;

[5-Allyloxy-1-(2-naphthalen-1-yl-ethyl)-1H-indol-3-yl]-oxo-acetic acid;

{5-Allyloxy-1-[2-(3-trifluoromethylphenyl)-ethyl]-1H-indol-3-yl}-oxo-aceticacid;

{5-Allyloxy-1-[2-(4-bromophenyl)-ethyl]-1H-indol-3-yl}-oxo-acetic acid;

or pharmaceutically acceptable salt or ester forms thereof.

The preferred salt forms of the compounds herein include but are notlimited to sodium salts, and potassium salts. Other useful salt forms ofthese compounds include those formed with pharmaceutically acceptableinorganic and organic bases known in the art. Salt forms prepared usinginorganic bases include hydroxides, carbonates or bicarbonates of thetherapeutically acceptable alkali metals or alkaline earth metals, suchas sodium potassium, magnesium, calcium and the like. Acceptable organicbases include amines, such as benzylamine, mono-, di- andtrialkylamines, preferably those having alkyl groups of from 1 to 6carbon atoms, more preferably 1 to 3 carbon atoms, such as methylamine,dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine,mono-, di-, and triethanolamine. Also useful are alkyl diaminescontaining up to 6 carbon atoms, such as hexamethylenediamine; cyclicsaturated or unsaturated bases containing up to 6 carbon atoms,including pyrrolidine, piperidine, morpholine, piperazine and theirN-alkyl and N-hydroxyalkyl derivatives, such as N-methyl-morpholine andN-(2-hyroxyethyl)-piperidine, or pyridine. Quaternary salts may also beformed, such as tetraalkyl forms, such as tetramethyl forms,alkyl-alkanol forms, such as methyl-triethanol or trimethyl-monoethanolforms, and cyclic ammonium salt forms, such as N-methylpyridinium,N-methyl-N-(2-hydroxyethyl)-morpholinium, N,N-di-methylmorpholinium,N-methyl-N-(2-hydroxyethyl)-morpholinium, or N,N-dimethyl-piperidiniumsalt forms. These salt forms may be prepared using the acidiccompound(s) of Formula I and procedures known in the art.

Ester forms of the compounds of this invention include straight chainalkyl esters having from 1 to 6 carbon atoms or branched chain alkylgroups containing 3 or 6 carbon atoms, including methyl, ethyl, propyl,butyl, 2-methylpropyl and 1,1-dimethylethyl esters. Other esters usefulwith this invention include those of the formula —COOR₉ wherein R₉ isselected from the formulae:

wherein R₁₀, R₁₁, R₁₂, and R₁₃ are independently selected from hydrogen,alkyl of from 1 to 10 carbon atoms, aryl of 6 to 12 carbon atoms,arylalkyl of from 6 to 12 carbon atoms; heteroaryl or alkylheteroarylwherein the heteroaryl ring is bound by an alkyl chain of from 1 to 6carbon atoms.

Among the preferred ester forms of the compounds herein include but notlimited to C₁–C₆ alkyl esters, C₃–C₆ branched alkyl esters, benzylesters, etc.

For purposes of this invention the term “alkyl” includes both straightand branched alkyl moieties, preferably of 1 to 8 carbon atoms. The term“alkenyl” refers to a radical aliphatic hydrocarbon containing onedouble bond and includes both straight and branched alkenyl moieties of2 to 7 carbon atoms. Such alkenyl moieties may exist in the E or Zconfigurations; the compounds of this invention include bothconfigurations. The term “alkynyl” includes both straight chain andbranched moieties containing 2 to 7 carbon atoms having at least onetriple bond. The term “cycloalkyl” refers to alicyclic hydrocarbongroups having 3 to 12 carbon atoms and includes but is not limited to:cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,norbornyl, or adamantyl. For purposes of this invention the term “aryl”is defined as an aromatic hydrocarbon moiety and may be substituted orunsubstituted. An aryl may be selected from but not limited to, thegroup: phenyl, α-naphthyl, β-naphthyl, biphenyl, anthryl,tetrahydronaphthyl, phenanthryl, fluorenyl, indanyl, biphenylenyl,acenaphthenyl, acenaphthylenyl, or phenanthrenyl groups.

For purposes of this invention the term “heteroaryl” is defined as anaromatic heterocyclic ring system (monocyclic or bicyclic) where theheteroaryl moieties are five or six membered rings containing 1 to 4heteroatoms selected from the group consisting of S, N, and O, andinclude but is not limited to: (1) furan, thiophene, indole, azaindole,oxazole, thiazole, isoxazole, isothiazole, imidazole, N-methylimidazole,pyridine, pyrimidine, pyrazine, pyrrole, N-methylpyrrole, pyrazole,N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4-triazole,1-methyl-1,2,4-triazole, 1H-tetrazole, 1-methyltetrazole, benzoxazole,benzothiazole, benzofuran, benzisoxazole, benzimidazole,N-methylbenzimidazole, azabenzimidazole, indazole, quinazoline,quinoline, pyrrolidinyl; (2) a bicyclic aromatic heterocycle where aphenyl, pyridine, pyrimidine or pyridazine ring is: (i) fused to a6-membered aromatic (unsaturated) heterocyclic ring having one nitrogenatom; (ii) fused to a 5 or 6-membered aromatic (unsaturated)heterocyclic ring having two nitrogen atoms; (iii) fused to a 5-memberedaromatic (unsaturated) heterocyclic ring having one nitrogen atomtogether with either one oxygen or one sulfur atom; or (iv) fused to a5-membered aromatic (unsaturated) heterocyclic ring having oneheteroatom selected from O, N or S.

For the purposes of this invention the term “alkoxy” is defined as C₁–C₆alkyl-O—; wherein alkyl is defined above.

For purposes of this invention the term “arylalkyl” is defined asaryl-C₁–C₆-alkyl-; arylalkyl moieties include benzyl, 1-phenylethyl,2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl and the like. For purposesof this invention the term “cycloalkylalkyl” denotes an alkyl group asdefined above that is further substituted with a cycloalkyl group asdefined above.

The compounds of the present invention are inhibitors of the serineprotease inhibitor PAI-1, and are therefore useful in the treatment,inhibition, prevention or prophylaxis in a mammal, preferably in ahuman, of those processes which involve the production and/or action ofPAI-1. Thus, the compounds of the invention are useful in the treatmentor prevention of noninsulin dependent diabetes mellitus andcardiovascular disease caused by such condition, and prevention ofthrombotic events associated with coronary artery and cerebrovasculardisease. These compounds are also useful for inhibiting the diseaseprocess involving the thrombotic and prothrombotic states which include,but are not limited to, formation of atherosclerotic plaques, venous andarterial thrombosis, myocardial ischemia, atrial fibrillation, deep veinthrombosis, coagulation syndromes, pulmonary fibrosis, cerebralthrombosis, thromboembolic complications of surgery (such as jointreplacement), and peripheral arterial occlusion. These compounds arealso useful in treating stroke associated with or resulting from atrialfibrillation.

The compounds of the invention may also be used in the treatment ofdiseases associated with extracellular matrix accumulation, including,but not limited to, renal fibrosis, chronic obstructive pulmonarydisease, polycystic ovary syndrome, restenosis, renovascular disease andorgan transplant rejection.

The compounds of the invention may also be used in the treatment ofmalignancies, and diseases associated with neoangiogenesis (such asdiabetic retinopathy).

The compounds in the invention may also be used in conjunction with andfollowing processes or procedures involving maintaining blood vesselpatency, including vascular surgery, vascular graft and stent patency,organ, tissue and cell implantation and transplantation.

The compounds in the invention may also be useful in the treatment ofinflammatory diseases, septic shock and the vascular damage associatedwith infections.

The compounds of the invention are useful for the treatment of blood andblood products used in dialysis, blood storage in the fluid phase,especially ex vivo platelet aggregation. The present compounds may alsobe added to human plasma during the analysis of blood chemistry inhospital settings to determine the fibrinolytic capacity thereof.

The compounds in the present invention may also be used in combinationwith prothrombolytic, fibrinolytic and anticoagulant agents.

The compounds of the present invention may also be used to treat cancerincluding, but not limited to, breast and ovarian cancer, and as imagingagents for the identification of metastatic cancers.

The compounds of the invention may also be used in the treatment ofAlzheimer's disease. This method may also be characterized as theinhibition of plasminogen activator by PAI-1 in a mammal, particularly ahuman, experiencing or subject to Alzhemier's disease. This method mayalso be characterized as a method of increasing or normalizing levels ofplasmin concentration in a mammal, particularly those experiencing orsubject to Alzheimer's disease.

The compounds of the invention may be used for the treatment ofmyelofibrosis with myeloid metaplasia by regulating stromal cellhyperplasia and increases in extracellular matrix proteins.

The compounds of the invention may also be used in conjunction withprotease inhibitor—containing highly active antiretroviral therapy(HAART) for the treatment of diseases which originate from fibrinolyticimpairment and hyper-coagulability of HIV-1 infected patients receivingsuch therapy.

The compounds of the invention may be used for the treatment of diabeticnephropathy and renal dialysis associated with nephropathy.

The compounds of the invention may be used to treat cancer, septicemia,obesity, insulin resistance, proliferative diseases such as psoriasis,improving coagulation homeostasis, cerebrovascular diseases,microvascular disease, hypertension, dementia, osteoporosis, arthritis,asthma, heart failure, arrhythmia, angina, and as a hormone replacementagent, treating, preventing or reversing progression of atherosclerosis,Alzheimer's disease, osteoporosis, osteopenia; reducing inflammatorymarkers, reducing C-reactive protein, or preventing or treating lowgrade vascular inflammation, stroke, dementia, coronary heart disease,primary and secondary prevention of myocardial infarction, stable andunstable angina, primary prevention of coronary events, secondaryprevention of cardiovascular events, peripheral vascular disease,peripheral arterial disease, acute vascular syndromes, reducing the riskof undergoing a myocardial revascularization procedure, microvasculardiseases such as nephropathy, neuropathy, retinopathy and nephroticsyndrome, hypertension, Type I and 2 diabetes and related diseases,hyperglycemia, hyperinsulinemia, malignant lesions, premalignantlesions, gastrointestinal malignancies, liposarcomas and epithelialtumors, proliferative diseases such as psoriasis, improving coagulationhomeostasis, and/or improving endothelial function, and all forms ofcerebrovascular diseases.

The compounds of the invention may be used for the topical applicationsin wound healing for prevention of scarring.

Methods for the treatment, inhibition, prevention or prophylaxis in amammal of each of the conditions or maladies listed herein are part ofthe present invention. Each method comprises administering to a mammalin need thereof a pharmaceutically or therapeutically effective amountof a compound of this invention, or a pharmaceutically acceptable saltor ester form thereof.

Each of the methods described herein comprise administering to a mammalin need of such treatment a pharmaceutically effective amount of acompound of this invention, or a pharmaceutically acceptable salt orester form thereof. It will be understood that a pharmaceuticallyeffective amount of the compound will be at least the minimum amountnecessary to provide an improvement in the symptoms or underlyingcausation of the malady in question or to inhibit or lessen the onset ofsymptoms of the malady.

The present invention is thus further directed to a method of inhibitingplasminogen activator inhibitor (PAI-1) in a mammal comprisingadministering to a mammal in need thereof a therapeutically effectiveamount of a compound of Formula (I):

wherein:

-   R₁ is: a) the moiety:

-   -   or    -   b) C₁–C₈ alkyl, benzo[1,3]dioxo-5yl-methyl, cycloalkylalkyl        where the alkyl chain is C₁–C₃, heteroarylalkyl where the alkyl        chain is C₁–C₃, arylalkyl where the alkyl chain is C₁–C₃,        preferably selected from benzyl, CH₂-1-naphthyl, CH₂-2-naphthyl,        CH₂CH₂-phenyl, or CH₂CH₂-naphthyl, wherein the alkyl,        cycloalkyl, heteroaryl, phenyl, benzyl, and naphthyl, groups may        be optionally substituted by from 1 to 3 groups selected from        halogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃ perfluoroalkyl,        C₁–C₃ alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio, C₁–C₃        perfluoroalkylthio, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —C(O)NH₂,        —S(O)₂CH₃, —OH, —NH₂, or —NO₂;

R₄ is hydrogen, halogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃perfluoroalkyl, C₁–C₃ alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio,C₁–C₃ perfluoroalkylthio, —OCHF₂, —CN, —COOH, —CH₂CO₂H, —C(O)CH₃,—CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂;

X is O, S, or NH;

R₅ is C₁–C₈ alkyl, C₁–C₃ perfluoroalkyl, C₃–C₆ cycloalkyl, —CH₂—C₃–C₆cycloalkyl, heteroaryl, —CH₂-heteroaryl, phenyl, or arylalkyl where thealkyl chain is C₁–C₈, wherein the rings of the cycloalkyl, heteroaryl,phenyl, and aryl groups may be optionally substituted by from 1 to 5groups selected from halogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃perfluoroalkyl, C₁–C₃ alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio,C₁–C₃ perfluoroalkylthio, —OCHF₂, —CN, —COOH, —CH₂CO₂H, —C(O)CH₃,—CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂;

R₂ is hydrogen, C₁–C₆ alkyl, —CH₂—C₃–C₆ cycloalkyl, or C₁–C₃perfluoroalkyl, wherein the alkyl and cycloalkyl groups may beoptionally substituted by halogen, —CN, C₁–C₆ alkoxy, —COOH, —CH₂CO₂H,—C(O)CH₃, —CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂;

R₃ is: (a) hydrogen, halogen, C₁–C₈ alkyl, C₁–C₈ alkenyl, C₁–C₈ alkynyl,C₃–C₆ cycloalkyl, —CH₂—C₃–C₆ cycloalkyl, heteroaryl, or phenyl, whereinthe alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and phenyl groupsmay be optionally substituted by from 1 to 3 groups selected fromhalogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃ perfluoroalkyl, C₁–C₃alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio, C₁–C₃perfluoroalkylthio, —OCHF₂, —CN, —COOH, —CH₂CO₂H, —C(O)CH₃, —CO₂R₇,—C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂;

or (b) the moiety X—R₆;

R₆ is C₁–C₈ alkyl, C₁–C₈ alkenyl, C₁–C₈ alkynyl, C₃–C₆ cycloalkyl,—CH₂—C₃–C₆ cycloalkyl, heteroaryl, phenyl, aryl-alkyl where the alkylchain is C₁–C₈, CH₂CH₂-phenyl, or CH₂CH₂-naphthyl, wherein the alkyl,alkenyl, alkynyl, cycloalkyl, heteroaryl, phenyl, and naphthyl groupsmay be optionally substituted by from 1 to 3 groups selected fromhalogen, C₁–C₃ alkyl, C₁–C₃ perfluoroalkyl, preferably —CF₃, —O—C₁–C₃perfluoroalkyl, preferably —OCF₃, —S—C₁–C₃ perfluoroalkyl, preferably—SCF₃, C₁–C₃ alkoxy, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —S(O)₂CH₃, —OH,—NH₂, or —NO₂; and

R₇ is C₁–C₆ alkyl, C₃–C₆ cycloalkyl, —CH₂—C₃–C₆ cycloalkyl, oraryl-alkyl where the alkyl chain is C₁–C₈; or a pharmaceuticallyacceptable salt or ester form thereof.

PROCESS OF THE INVENTION

Compounds of the present invention can be readily prepared according tothe methods and examples described below using readily availablestarting materials, reagents and conventional synthetic procedures. Itis also possible to make use of variants of these process steps, whichin themselves are known to and well within the preparatory skill of themedicinal chemist. In the following reaction schemes, R₁ through R₈ areselected from the groups defined above.

Method A

Substituted indole is first arylated on nitrogen with aryl iodides,bromides, chlorides, and triflates having a suitable handle for furtherelaboration. This handle can be, but is not limited to, an ethersubstituent, such as methoxy or benzyloxy. Indole may be arylated onnitrogen by reaction with aryl halides, especially aryl iodides, in thepresence of copper (I) or copper (II) salts and base in a solvent suchas pyridine, collidine, dimethylformamide (DMF), N-methylpyrrolidinone(NMP), or DMSO at elevated temperatures of 100 to 210° C. IndoleN-arylation can also be carried out with aryl iodides, bromides,chlorides, and triflates in the presence of a base, preferably NaOt-Buor K₃PO₄, and bulky, electron rich phosphine ligands in combination withPd₂(dba)₃ in an inert solvent such as toluene at 80 to 100° C. The etherprotecting group may then be removed by any convenient means, e.g., formethyl ethers, treatment with BBr₃ in an inert solvent such asdichloromethane (DCM) at −78 to +25° C. or, for benzyl ethers,hydrogenation over palladium on carbon (Pd—C) in a polar solvent, suchas methanol. The hydroxyl group can then in turn be alkylated with analkyl or benzyl iodide, bromide, chloride, or triflate in the presenceof a base, such as KOH or NaH, in an inert solvent, such as THF,dioxane, pyridine, DMF, NMP, or DMSO, at −40 to +100° C. The product canthen be reacted with 1–100 equivalents oxalyl chloride, either neat orin an inert solvent such as DCM, THF, or dioxane, at −40 to +64° C. Theresulting glyoxylic chloride intermediate can be hydrolyzed with wateror with an aqueous solution of base, such as Na₂CO₃, NaHCO₃, or NaOH.The resulting solution may be acidified and extracted with a hydrophobicsolvent such as dichloromethane or ethyl acetate to isolate the product.

3- or 4-hydroxy indole can be alkylated in the presence of benzyl,diphenylmethyl or naphthylmethyl iodide, bromide, chloride, or triflatein the presence of a base, such as KOH or NaH, in an inert solvent, suchas THF, dioxane, pyridine, DMF, NMP, or DMSO, at −40 to +100° C. Theresulting ether can be selectively deprotected via hydrogenation,preferably by transfer hydrogenation, using Pd—C, a hydrogen source,such as H₂, NH₄CHO, NH₄OAc, HCO₂H, cyclohexadiene, or isopropyl alcohol,either neat or in a solvent, such as methanol, ethanol, or propanol, at25–100° C. The resulting hyroxy indole can the be O-arylated with arylfluoride, chloride, bromide, or iodide in the presence of a base, suchas Cs₂CO₃ or K₂CO₃, in an inert solvent such as pyridine, collidine,DMF, NMP, or DMSO at 25–110° C. The ether intermediate can be convertedto the glyoxylic acid product using the procedure described in Method A,above.

5-Hydroxyindole can be O-alkylated with aliphatic alcohols in thepresence of triphenylphosphine and azodicarboxylates, especiallydiethyl, diisopropyl, or di-t-butyl azodicarboxylates, in an inertsolvent, preferably THF, at 0–25° C. Alternately,N-benzyl-5-hydroxyindole can be prepared according to the proceduredescribed above in Method B and alkylated in the presence of alkyl,benzyl, phenethyl, or naphthylmethyl iodide, bromide, chloride, ortriflate in the presence of a base, such as K₂CO₃, Cs₂CO₃, KOH or NaH,in an inert solvent, such as THF, dioxane, pyridine, DMF, NMP, or DMSO,at −40 to +100° C. The 1H-indole intermediate can be alkylated in turnwith alkyl, benzyl, phenethyl, or naphthylmethyl iodide, bromide,chloride, or triflate as just described. The resulting N,O-alkylatedindole can be reacted with oxalyl chloride as described above to formthe product.

This invention also provides pharmaceutical compositions comprising ofthe present invention either alone or in combination with one or morepharmaceutically acceptable carriers or excipients. Such compositionsfor treating conditions resulting from fibrinolytic disorder such asdeep vein thrombosis and coronary heart disease, pulmonary fibrosis,etc.

The precise dosage to be employed depends upon several factors includingthe host, whether in veterinary medicine or human medicine, the natureand severity of the condition being treated, the mode of administrationand the particular active substance employed. The compounds may beadministered by any conventional route, in particular enterally,preferably orally in the form of tablets or capsules. Administeredcompounds can be in the free form or pharmaceutically acceptable saltform as appropriate, for use as a pharmaceutical, particularly for usein the prophylactic or curative treatment of atherosclerosis andsequelae (angina pectoris, myocardial infarction, arrhythmias, heartfailure, kidney failure, stroke, peripheral arterial occlusion, andrelated disease states). These measures will slow the rate of progressof the disease state and assist the body in reversing the processdirection in a natural manner.

Any suitable carrier known to the art can be used to prepare thepharmaceutical compositions. In such a composition, the carrier may be asolid, liquid or mixture of a solid and a liquid. Solid compositionsinclude powders, tablets and capsules. A solid carrier can be one ormore substances which may also act as a flavoring agent, lubricant,solubilizer, suspending agent, binder, or tablet disintegrant. Inpowders, the carrier is a finely divided solid, which is in admixturewith the finely divided active ingredient. In tablets, the activeingredient is mixed with a carrier having the necessary bindingproperties in suitable proportions and compacted in the shape and sizedesired. Suitable solid carriers are magnesium carbonate, magnesiumstearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin,tragacanth, methyl cellulose, hydroxymethyl cellulose, sodiumcarboxymethyl cellulose, a low melting wax, cocoa butter, and the like.Encapsulating materials may also be employed with the compounds of thisinvention, and the term “composition” is intended to include the activeingredient in combination with an encapsulating material as aformulation, with or without other carriers. Cachets may also be used inthe delivery of the anti-atherosclerotic medicament of this invention.

Sterile liquid compositions include solutions, suspensions, emulsions,syrups and elixirs. The compounds of this invention may be dissolved orsuspended in the pharmaceutically acceptable carrier, such as sterilewater, sterile organic solvent or a mixture of both. Preferably theliquid carrier is one suitable for parental injection. Where thecompounds are sufficiently soluble they can be dissolved directly innormal saline with or without the use of suitable organic solvents, suchas propylene glycol or polyethylene glycol. If desired, dispersions ofthe finely divided compounds can be made-up in aqueous starch or sodiumcarboxymethyl cellulose solution, or in a suitable oil, such as arachisoil. Liquid pharmaceutical compositions, which are sterile solutions orsuspensions, can be utilized by intramuscular, intraperitoneal orsubcutaneous injection. In many instances a liquid composition form maybe used instead of the preferred solid oral method of administration.

It is preferred to prepare unit dosage forms of the compounds forstandard administration regimens. In this way, the composition can besubdivided readily into smaller doses at the physician's direction. Forexample, unit dosages may be made up in packeted powders, vials orampoules and preferably in capsule or tablet form. The active compoundpresent in these unit dosage forms of the composition may be present inan amount of from about one gram to about fifteen grams or more, forsingle or multiple daily administration, according to the particularneed of the patient. The daily dose of active compound will varydepending upon the route of administration, the size, age and sex of thepatient, the severity of the disease state, and the response to thetherapy as traced by blood analysis and the patients recovery rate. Byinitiating the treatment regimen with a minimal daily dose of about onegram, the blood levels of PAI-1 and the patients symptomatic reliefanalysis may be used to determine whether a larger dose is indicated.Based upon the data presented below, the projected daily dose for bothhuman and veterinary use will be from about 25 to about 200milligrams/kilogram per day, and more usually, from about 50 to about100 milligrams/kilogram per day.

The ability of the compounds of this invention to inhibit PlasminogenActivator Inhibitor-1 was established by the following experimentalprocedures:

Primary Screen for the PAI-1 Inhibition

Test compounds were dissolved in DMSO at a final concentration of 10 mM,then diluted 100× in physiologic buffer. The inhibitory assay wasinitiated by the addition of the test compound (1–100 μM finalconcentration, maximum DMSO concentration of 0.2%) in a pH 6.6 buffercontaining 140 nM recombinant human plasminogen activator inhibitor-1(Molecular Innovations, Royal Oak, Mich.). Following a 1 hour incubationat room temperature, 70 nM of recombinant human tissue plasminogenactivator (tPA) was added, and the combination of the test compound,PAI-1 and tPA was incubated for an additional 30 minutes. Following thesecond incubation, Spectrozyme-tPA (American Diagnostica, Greenwich,Conn.), a chromogenic substrate for tPA, was added and absorbance readat 405 nm at 0 and 60 minutes. Relative PAI-1 inhibition was equal tothe residual tPA activity in the presence of the test compound andPAI-1. Control treatments included the complete inhibition of tPA byPAI-1 at the molar ratio employed (2:1), and the absence of any effectof the test compound on tPA alone.

Assay for Determining IC₅₀ of Inhibition of PAI-1

This assay was based upon the non-SDS dissociable interaction betweentPA and active PAI-1. Assay plates were initially coated with human tPA(10 μg/ml). The test compounds were dissolved in DMSO at 10 mM, thendiluted with physiologic buffer (pH 7.5) to a final concentration of1–50 μM. The test compounds were incubated with human PAI-1 (50 ng/ml)for 15 minutes at room temperature. The tPA-coated plate was washed witha solution of 0.05% Tween 20 and 0.1% BSA, then the plate is blockedwith a solution of 3% BSA. An aliquot of the test compound/PAI-1solution was then added to the tPA-coated plate, incubated at roomtemperature for 1 hour, and washed. Active PAI-1 bound to the plate wasassessed by adding an aliquot of a 1:1000 dilution of the 33B8monoclonal antibody against human PAI-1, and incubating the plate atroom temperature for 1 hour (Molecular Innovations, Royal Oak, Mich.).The plate was again washed, and a solution of goat anti-mouseIgG-alkaline phosphatase conjugate is added at a 1:50,000 dilution ingoat serum. The plate was incubated 30 minutes at room temperature,washed, and a solution of alkaline phosphatase substrate was added. Theplate was incubated 45 minutes at room temperature, and colordevelopment was determined at OD_(405nm). The quantitation of activePAI-1 bound to tPA at varying concentrations of the test compound wasused to determine the IC₅₀. Results were analyzed using a logarithmicbest-fit equation. The assay sensitivity was 5 ng/ml of human PAI-1 asdetermined from a standard curve ranging from 0–100 ng/ml.

The compounds of the present invention inhibited Plasminogen ActivatorInhibitor-1 as summarized in Table I.

TABLE 1 Inhibition Example @25 uM (%) IC₅₀ (uM) 1 23 — 2 43 — 3 78 >25 440 (100 uM) — 5 26 — 6 54 >25 7 62 — 8 34 (100 uM) — 9 44 — 10  1 — 1166 — 12 32 (100 uM) — 13 39 — 14 43 — 15  5 — 16 75 >25 17 49 (100 uM) —18 45 — 19 46 — 20 56 >25 21  6 — 22 13 — 23 52    12.32 24 13 (100 uM)— 25  8 (100 uM) — 26  8 (100 uM) — 27 16 (100 uM) — 28 12 — 29 29 (100uM) — 30 29 —

EXAMPLE 1 (1-{4-[(4-Cyanobenzyl)oxy]phenyl}-1H-indol-3-yl)(oxo)aceticacid

Step 1

A slurry of 2.63 g (22.5 mmol) indole, 5.26 g (22.5 mmol) 4-iodoanisole,0.43 g (3 mmol) CuBr and 4.14 g (30 mmol) K₂CO₃ in 60 ml anhydrousN-methylpyrrolidinone (NMP) was heated to reflux with stirring for 16hr. The solution was allowed to cool and then poured into water andshaken with ethyl acetate. The entire biphasic system was filteredthrough a pad of Celite, the phases were separated, and the organicphase was dried over MgSO₄ and concentrated. The crude product waschromatographed on silica (5–7% EtOAc-Hexane) to afford 3.53 g1-(4-methoxyphenyl)-1H-indole as a colorless solid.

Step 2

To 2.90 g (13 mmol) 1-(4-methoxyphenyl)-1H-indole in 80 ml anhydrous DCMat −78° C. was added 2.27 ml (24 mmol) BBr₃. The solution was allowed togradually warm to room temperature overnight. The solution was pouredinto a slurry of ice and water. Brine was added and the product wasextracted with ethyl acetate. The organic phase was dried over MgSO₄ andconcentrated. The crude product was chromatographed on SiO₂ to afford0.73 g 1-(4-hydroxyphenyl)-1H-indole as an oil.

Step 3

To a solution of 0.038 g (0.18 mmol) 1-(4-hydroxyphenyl)-1H-indole in1.2 ml DMF was added 0.05 g (0.38 mmol) K₂CO₃ and the slurry was mixedfor 30 min. 59 mg (0.3 mmol) α-bromo-p-tolunitrile and 0.01 g (66 μmol)NaI was added and the slurry was mixed at 60° C. for 4 hr. The solutionwas allowed to cool and an additional 2 ml DMF was added, followed by0.10 g PS-Trisamine scavenger reagent (Argonaut Technologies, SanCarlos, Calif.). The slurry was mixed at 60° C. for a further 3 hr andallowed to cool. The reaction was filtered and the solution wasconcentrated to afford 0.045 g1-{4-[(4-cyanobenzyl)oxy]phenyl}-1H-indole as an oil.

Step 4

To a solution of the product from Part 3 in 1 ml THF was added 200 μl of1M (COCl)₂ in THF. The solution was mixed 5 min upon which time anadditional 200 μl 1M (COCl)₂ was added. The solution was heated to 55°C. for 6 hr and allowed to cool. The solution was drained from thereaction vessel into a vial containing 2 ml aqueous NaHCO₃ and thebiphasic system was mixed overnight whereupon 1 ml 2N aqueous HCl wasadded. The product was extracted with 2 ml DCM, the organic phaseseparated and concentrated. The residue was purified by RP-HPLC (SeeNote 1 below) to give(1-{4-[(4-cyanobenzyl)oxy]phenyl}-1H-indol-3-yl)(oxo)acetic acid (19.9mg) as an oil. LC/MS Data (See Note 2 below) (molecular ion andretention time): m/z 397 (M+H); 1.97 min.

Note 1. Semi-preparative RP-HPLC Conditions:

-   -   Gilson Semi-Preparative HPLC system with Unipoint Software    -   Column: Phenomenex C₁₈ Luna 21.6 mm×60 mm, 5 μM;    -   Solvent A: Water (0.02% TFA buffer); Solvent B: Acetonitrile        (0.02% TFA buffer); Solvent Gradient: Time 0: 5% B; 2.5 min: 5%        B; 7 min: 95% B; Hold 95% B 5 min.    -   Flow Rate: 22.5 mL/min

The product peak was collected based on UV absorption and concentrated.

Note 2. Analytical LC/MS Conditions:

Hewlett Packard 1100 MSD with ChemStation Software

Column: YMC ODS-AM 2.0 mm×50 mm 5μ column at 23° C.

Solvent A: Water (0.02% TFA buffer)

Solvent B: Acetonitrile (0.02% TFA buffer)

Gradient: Time 0: 5% B; 0.3 min: 5% B; 3.0 min: 90% B; Hold 95% B 2 min.

Flow rate 1.5 mL/min

Detection: 254 nm DAD; API-ES Scanning Mode Positive 150–700; Fragmentor70 mV.

The compounds of Examples 2–19 were prepared by the same steps as setforth in Example 1 using indole, 5-fluoroindole, 5-methylindole,5-chloroindole, 4-iodoanisole, 3-iodoanisole, α-bromo-p-tolunitrile,3-methoxybenzylbromide, 3-chlorobenzylbromide,3,5-dimethoxybenzylbromide, 4-t-butylbenzylbromide,2,4-dichlorobenzylbromide, 2,3,5,6-tetrafluoro-4-(trifluoromethyl)benzylbromide, 4-(4-bromomethyl)phenyl-1,2,3-thiadiazole,4-(bromomethyl)-2,6-dichloropyridine, and ethyl 5-chloromethylfurancarboxylate.

Ex- am- m/z, Retention Time ple Chemical Name (min) 2{1-[4-(3-Methoxybenzyloxy)phenyl]- 402 (M + H); 2.25 min1H-indol-3-yl}(oxo)acetic acid 3 {1-[4-(3-Chlorobenzyloxy)phenyl]- 402(M + H); 2.25 min 1H-indol-3-yl}(oxo)acetic acid 4{1-[4-(4-Cyanobenzyloxy)phenyl]-5- fluoro-1H-indol-3-yl}(oxo)acetic acid5 {1-[4-(3,5-Dimethoxybenzyloxy) 450 (M + H); 2.30 minphenyl]-5-fluoro-1H-indol-3- yl}(oxo)acetic acid 6{1-[4-(3-Chlorobenzyloxy)phenyl]-5- 420 (M + H); 2.90 min³methyl-1H-indol-3-yl}(oxo)acetic acid 7 {1-[4-(4-tert-Butylbenzyloxy)442 (M + H); 3.45 min phenyl]-5-methyl-1H-indol-3- yl}(oxo)acetic acid 8{1-[4-(2,4-Dichlorobenzyloxy) phenyl]-5-methyl-1H-indol-3-yl}(oxo)acetic acid 9 {5-Chloro-1-[3-(4-cyanobenzyloxy) 431 (M + H);2.35 min phenyl]-1H-indol-3-yl}(oxo)acetic acid 10{5-Chloro-1-[3-(3,5-dimethoxy benzyloxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid 11 {1-[4-(2,3,5,6-tetrafluoro-4- 512 (M + H); 2.88min trifluoromethylbenzyloxy)phenyl]1H- indol-3-yl}(oxo)acetic acid 12{1-[4-(4-[1,2,3]thiadiazol-4- ylbenzyloxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid 13 {1-[4-(2,6-Dichloropyridin-4- 441 (M + H); 2.42min ylmethoxy)phenyl]1H-indol-3- yl}(oxo)acetic acid 145-[4-(5-Fluoro-3-carboxy(oxo) 452 (M + H); 1.97 minmethyl-1H-indol-1-yl)phenoxy methyl]furan-2-carboxylic acid ethyl ester15 {1-[4-(2,6-dichloropyridin-4- ylmethoxy)phenyl]-5-methyl-1H-indol-3-yl}(oxo)acetic acid 16 {5-Chloro-1-[3-(2,3,5,6-tetrafluoro-4-trifluoromethylbenzyloxy) phenyl]1H- indol-3-yl}(oxo)acetic acid 175-[3-(5-Chloro-3-carboxy(oxo) methyl-1H-indol-1-yl)phenoxymethyl]furan-2-carboxylic acid ethyl ester 18{5-Chloro-1-[3-(4-[1,2,3]thiadiazol-4- 490 (M + H); 2.57 minylbenzyloxy)phenyl]-1H-indol-3- yl}(oxo)acetic acid 19{5-Chloro-1-[3-(2,6-dichloropyridin- 475, 477 (M + H);4-ylmethoxy)phenyl]-1H-indol-3- 2.80 min yl}(oxo)acetic acidNote 3. Example 5 was resynthesized on a larger scale by a differentroute and recrystalized from EtOAc to give a yellow solid: m.p. 175–177°C.; ¹H NMR (CDCl₃, 400 MHz) δ 2.49 (s, 3H), 5.23 (s, 2H), 7.17 (d, J=8Hz, 1H), 7.25 (d, J=8 Hz, 2H), 7.34 (d, J=8 Hz, 1H), 7.40–7.50 (m, 3H),7.57–7.63 (m, 4H), 8.10 (s, 1H), 8.47 (s, 1H); MS: m/z (ESI) 420 (M+H);Anal. calcd for (C₂₄H₁₈ClNO₄) C, H, N.

EXAMPLE 20[1,5-Bis-(4-trifluoromethoxy-phenyl)-1H-indol-3-yl]-oxo-acetic acid

Step 1

A stirred slurry of 6.56 g (62 mmol) Na₂CO₃, 3.03 g (15.5 mmol)5-bromoindole, 3.415 g (16.5 mmol) 4-(trifluoromethoxy)phenylboronicacid, and 0.50 g (0.43 mmol) tetrakistriphenylphosphine palladium washeated to reflux for 3 hr. The reaction mixture was allowed to cool andwas then poured into 300 mL water and shaken with ethyl acetate. Thecombined aqueous and organic phases were filtered and the organic layerwas separated, dried over MgSO₄, and concentrated. The residue waschromatographed on silica (eluting with 20–33% EtOAc-hexane) to afford2.49 g (58%) 5-[4-(trifluoromethoxy)phenyl]indole as a solid.

Step 2

A mixture of 0.6 g (2.6 mmol) 5-(4-trifluoromethoxy-phenyl)-1H-indole,0.53 mL (2.8 mmol) 4-(trifluoromethoxy)iodobenzene, 0.075 g (0.52 mmol)copper(I) bromide and 0.54 g (3.9 mmol) K₂CO₃ in 10 mL anhydrousN-methylpyrrolidinone was heated to reflux overnight with stirring. Thereaction was allowed to cool and was then poured into 200 mL of water.The aqueous solution was shaken with 200 mL ethyl acetate, the combinedaqueous and organic phases were filtered, and the organic phase wasseparated. The aqueous phase was extracted once more with 200 mL ethylacetate and the combined organic phases were washed with brine andconcentrated. The crude product was chromatographed on silica (5–7%EtOAc-hexane as elutant) to afford 0.505 g (44% yield) of1,5-bis-(4-trifluoromethoxy-phenyl)-1H-indole.

Step 3 of Example 14 was conducted using the Quest 210 ParallelSynthesizer (Argonaut Technologies, San Carlos, Calif.) using 5 mLTeflon reaction vessels. Mixing of the reaction mixtures was achieved bythe vertical motion of a magnetic stir bar within the reaction vessel.Drainage of the reaction vessels was accomplished by the application ofa positive pressure of nitrogen to the reaction vessel.

Step 3

To a solution of 0.505 g (1.15 mmol)1,5-bis-(4-trifluoromethoxy-phenyl)-1H-indole in 3 mL anhydrous THF wasadded 0.13 mL (2.9 mmol) oxalyl chloride. The solution was mixed at roomtemperature for 18 hr, upon which time the contents of the reactionvessel were drained into a vial containing 10 mL aqueous NaHCO₃. Thevial was capped and shaken and then the solution was acidified by thedropwise addition of 10 mL 2N aqueous HCl. The organic phase was removedand concentrated. The crude product was purified by RP-HPLC (See Note 1)to afford 0.142 g[1,5-bis-(4-trifluoromethoxy-phenyl)-1H-indol-3-yl]-oxo-acetic acidethyl ester.

Step 4

To a solution of 0.142 g[1,5-bis-(4-trifluoromethoxy-phenyl)-1H-indol-3-yl]-oxo-acetic acidethyl ester from Step 3 in 1 mL THF was added 2 ml 0.5M aqueous LiOH.The reaction was mixed using orbital shaking for 5 hr, at which time TLCindicated that the reaction was complete. The solution was acidified bythe dropwise addition of 2N aqueous HCl and extracted withdichloromethane. The organic phase was dried by filtration through aChemElute column (Varian Inc., Palo Alto, Calif.) and the solvent wasevaporated to afford 82 mg[1,5-Bis-(4-trifluoromethoxy-phenyl)-1H-indol-3-yl]-oxo-acetic acid as ayellow solid: ¹H NMR (CDCl₃, 400 MHz) δ 9.13 (s, 1H), 8.64 (s, 1H), 7.70(d, J=6.6 Hz, 2H), 7.57–7.68 (m, 3H), 7.46–7.56 (m, 3H), 7.33 (d, J=8Hz, 2H), MS: m/z (ESI) 508.2 (M−H);

EXAMPLE 21{1-(4-fluorobenzyl)-5-[2-(4-fluorophenyl)ethoxy]-1H-indol-3-yl}(oxo)aceticacid

Step 1

To a solution of 1.06 g (8 mmol) 5-hydroxyindole and 2.09 g (8 mmol)triphenylphosphine in 40 ml anhydrous THF, cooled to 0° C. in ice, wasadded 1.0 mL (8 mmol) 4-fluorophenethylalcohol and 1.6 ml (8 mmol)diisopropylazodicarboxylate. The solution was allowed to gradually cometo room temperature overnight. The solution was concentrated and theresidue was chromatographed on silica using 20–25% EtOAc-hexane toafford 0.525 g 5-[2-(4-fluoro-phenyl)-ethoxy]-1H-indole as a whitesolid.

Step 2

To 0.2 g of a 60% dispersion of NaH in mineral oil, suspended in 20 mlof anhydrous THF, was added 0.61 g (2.38 mmol)5-[2-(4-fluoro-phenyl)-ethoxy]-1H-indole from Step 1. The slurry wasstirred for 15 min upon which time 0.33 ml (2.6 mmol)4-fluorobenzylbromide was added. The slurry was stirred overnight. Theslurry was concentrated under vacuum and the residue was redissolved inethyl acetate and washed with brine. The organic phase was dried overMgSO₄ and concentrated. The residue was chromatographed on silica toafford 0.61 g1-(4-fluoro-benzyl)-5-[2-(4-fluoro-phenyl)-ethoxy]-1H-indole as a fluffypowder.

Step 3

To a solution of the product from Part 3 in 10 ml anhydrous THF wasadded 0.30 ml of (COCl)₂. The solution was stirred at room temperatureover 4 nights. The solution was poured into a flask containing 20 mlaqueous NaHCO₃. 10 ml 2N aqueous HCl was added to acidify, the solutionwas extracted with DCM, and the organic phase was concentrated. Theresidue was purified by RP-HPLC (See Note 1 above) to give 0.43 g asyellow crystals: m.p. 171–173° C.; ¹H NMR (CDCl₃, 400 MHz) δ 3.10 (t,J=6.8 Hz, 2H), 4.24 (t, J=6.8 Hz, 2H), 5.33 (s, 2H), 6.90–6.93 (m, 1H),6.97–7.05 (m, 4H), 7.14–7.18 (m, 3H), 7.24–7.28 (m, 2H), 7.85 (s, 1H),8.92 (s, 1H); MS: m/z (ESI) 434 (M−H).

EXAMPLE 22 (1-Benzyl-5-benzyloxy-1H-indol-3-yl)-oxo-acetic acid

Using 1-benzyl-5-benzyloxy-1H-indole,(1-benzyl-5-benzyloxy-1H-indol-3-yl)-oxo-acetic acid was preparedfollowing the procedure of Step 3 of Example 21: ¹H NMR (CDCl₃, 400 MHz)δ 8.60 (s, 1H), 7.79 (d, J=2.5 Hz, 1H), 7.45–7.52 (m, 3H), 7.25–7.43 (m,7H), 6.99 (dd, J=6.8, 2.5 Hz, 1H), 5.55 (s, 2H), 5.13 (s, 2H), MS: m/z(ESI) 386 (M+H).

EXAMPLE 23[1-Benzyl-5-(2-chloro-4-trifluoromethyl-phenoxy)-1H-indol-3-yl](oxo)aceticacid

A slurry of 0.98 g (3.12 mmol) 1-benzyl-5-benzyloxy-1H-indole, 0.20 g20% Palladium on carbon, and 1.51 g (24 mmol) NH₄CHO was heated toreflux with stirring for 3 days. The reaction was allowed to cool and anadditional 0.20 g 20% Palladium on carbon and 1.33 g NH₄CHO was added.The reaction was refluxed for an additional 24 hours upon which time thereaction was complete by TLC. The reaction was filtered through paperand concentrated. The residue was chromatographed on silica using 25–40%EtOAc-hexane to afford 0.44 g 1-benzyl-5-hydroxy-1H-indole as a solid.

Step 2

A slurry of 0.413 g (1.85 mmol) 1-benzyl-5-hydroxy-1H-indole, 0.3 ml(2.2 mmol) 3-chloro-4-fluorobenzotrifluoride, and 1.0 g (3.0 mmol)Cs₂CO₃ in 12 ml DMF was heated to 130° C. with stirring for 16 hr. Thesolution was allowed to cool and then filtered to remove Cs₂CO₃. Thesolution was concentrated under vacuum and chromatographed on silicausing 5–7% EtOAc-hexane to afford 0.51 g1-benzyl-5-(2-chloro-4-trifluoromethyl-phenoxy)-1H-indole as an oil.

Step 3

To a solution of the product from Part 2 in 8 ml anhydrous THF was added0.22 ml of (COCl)₂. The solution was stirred at room temperature for 4hr. 10 ml saturated aqueous NaHCO₃ was added and the biphasic system wasstirred for ½ hr. 2N aqueous HCl was added to acidify, the solution wasextracted with DCM, and the organic phase was concentrated. The residuewas purified by RP-HPLC¹ to give 0.315 g as yellow crystals: m.p.152–154° C.; ¹H NMR (CDCl₃, 400 MHz) δ 5.42 (s, 2H), 6.89 (d, J=4.4 Hz,1H), 7.05 (dd, J=6.2 Hz, 1.2 Hz, 1H), 7.20–7.25 (m, 2H), 7.34–7.40 (m,5H), 7.74 (s, 1H), 8.06 (s, 1H), 9.04 (s, 1H); MS: m/z (ESI) 472 (M−H).

EXAMPLE 24 (5-Allyloxy-1-cyclobutylmethyl-1H-indol-3-yl)-oxo-acetic acid

To a slurry of 2.92 g (22 mmol) 5-hydroxyindole and 12.43 g (90 mmol)K₂CO₃ in 110 mL acetone was added 2.07 mL (24 mmol) allyl bromide. Thereaction was stirred at room temperature over 2 days upon which time TLCindicated that the reaction was not complete. Additional 0.66 mL allylbromide was added and the reaction was heated to reflux for 1.5 hr andstirred at room temperature over night. The reaction was filtered toremove precipitate and concentrated. The crude product waschromatographed on silica gel using 20–33% EtOAc-hexane to afford 3.128g (18 mmol) 5-allyloxyindole as an oil.

Step 2

To a slurry of 0.45 g (9.4 mmol) sodium hydride (50% dispersion inmineral oil) in 40 mL anhydrous THF was added 1.90 g 5-allyloxyindole.The slurry was stirred at room temperature for 15 min upon which time1.14 mL (9 mmol) benzene sulfonyl chloride was added dropwise. Thereaction was stirred at room temperature over three nights and thenpoured into water and extracted with ethyl acetate. The organic extractswere dried over MgSO₄ and concentrated. The product solidified uponconcentration and the crude material was triturated with diethyl etherto afford 1.36 g of 5-allyloxy-1-benzenesulfonyl-1H-indole as a lightbrown solid.

Step 3

To a solution of 43 mg (0.14 mmol)5-allyloxy-1-benzenesulfonyl-1H-indole in 1.6 mL toluene in a screw-capvial was added 31 μL (0.4 mmol) cyclobutanemethanol and 0.66 mL 0.6Msolution of sodium bis(trimethylsilylamide) in toluene. The solution washeated to 100° C. overnight with orbital shaking. The reaction wasconcentrated and the crude product was redissolved in 2.4 mL 1N aqueousHCl and the aqueous solution was extracted with 1.6 mL dichloromethane.The phases were separated and the organic phase was concentrated and theresidue was dried under vacuum with moderate heating (approximately 50°C.) overnight.

Step 4

The crude 5-allyloxy-1-cyclobutylmethyl-1H-indole from Step 3 wasdissolved in 0.5 mL anhydrous THF and 0.22 mL (2.5 mmol) oxalyl chloridewas added. The reaction was mixed overnight on an orbital shaker. Thereaction was concentrated and the crude product was redissolved in aminimum volume of dichloromethane. 0.8 mL 1N aqueous NaOH was added andthe reaction was capped and shaken. The solution was acidified by thedropwise addition of 2N aqueous HCl and extracted with 1.6 mLdichloromethane. LC/MS (see Note 2) indicated that the reaction was notcomplete. The crude material was redissolved in 0.5 mL anhydrous THF,0.16 mL oxalyl chloride was added, and the reaction was mixed at 40° C.for 6 hr with orbital shaking. The reaction was worked up as describedpreviously and the crude products were purified by RP-HPLC (see Note 1)to afford 6.2 mg (19.8 μmol)(5-allyloxy-1-cyclobutylmethyl-1H-indol-3-yl)-oxo-acetic acid: LC/MSData (molecular ion and retention time): m/z 312 (M−H); 2.49 min.

Using the procedures set forth in Steps 3 and 4 of Example 24 and usingphenethylalcohol, piperonyl alcohol, 4-methoxyphenethyl alcohol,1-napthyleneethanol, 3-trifluoromethylphenethyl alcohol, and4-bromophenethyl alcohol, compounds of Examples 25–30 were prepared.

Example Chemical Name m/z, Retention Time 25(5-Allyloxy-1-phenethyl-1H-indol- 348 (M − H); 2.62 min 3-yl)-oxo-aceticacid 26 (5-Allyloxy-1-benzo[1,3]dioxol-5- 378 (M − H); 2.64 minylmethyl-1H-indol-3-yl)-oxo-acetic acid 27 {5-Allyloxy-1-[2-(4-methoxy-378 (M − H); 2.57 min phenyl)-ethyl]-1H-indol-3-yl}-oxo- acetic acid 28[5-Allyloxy-1-(2-naphthalen-1-yl- 398 (M − H); 2.84 minethyl)-1H-indol-3-yl]-oxo-acetic acid 29 {5-Allyloxy-1-[2-(3- 416 (M +H); 2.82 min trifluoromethylphenyl)-ethyl]-1H- indol-3-yl}-oxo-aceticacid 30 {5-Allyloxy-1-[2-(4-bromophenyl)- 428 (M + H); 2.79 minethyl]-1H-indol-3-yl}-oxo-acetic acid

1. A compound of formula I:

wherein: R₁ is the moiety:

R₄ is hydrogen, halogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃perfluoroalkyl, C₁–C₃ alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio,C₁–C₃ perfluoroalkylthio, —OCHF₂, —CN, —COOH, —CH₂CO₂H, —C(O)CH₃,—CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂; X is O; R₅ is C₁–C₈alkyl, C₁–C₃ perfluoroalkyl, C₃–C₆ cycloalkyl, —CH₂—C₃–C₆ cycloalkyl,heteroaryl, —CH₂-heteroaryl, phenyl, or arylalkyl where the alkyl chainis C₁–C₈, wherein the rings of the cycloalkyl, heteroaryl, phenyl, andaryl groups are optionally substituted by from 1 to 5 groups selectedfrom halogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃ perfluoroalkyl, C₁–C₃alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio, C₁–C₃perfluoroalkylthio, —OCHF₂, —CN, —COOH, —CH₂CO₂H, —C(O)CH₃, —CO₂R₇,—C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂; R₂ is hydrogen, C₁–C₆ alkyl,—CH₂—C₃–C₆ cycloalkyl, or C₁–C₃ perfluoroalkyl, wherein the alkyl andcycloalkyl groups are optionally substituted by halogen, —CN, C₁–C₆alkoxy, —COOH, —CH₂CO₂H, —C(O)CH₃, —CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH,—NH₂, or —NO₂; R₃ is: (a) hydrogen, halogen, C₁–C₈ alkyl, C₁–C₈ alkenyl,C₁–C₈ alkynyl, C₃–C₆ cycloalkyl, —CH₂—C₃–C₆ cycloalkyl, heteroaryl, orphenyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, andphenyl groups are optionally substituted by from 1 to 3 groups selectedfrom halogen, C₁–C₃ alkyl, C₁–C₃ haloalkyl, C₁–C₃ perfluoroalkyl, C₁–C₃alkoxy, C₁–C₃ perfluoroalkoxy, C₁–C₃ alkylthio, C₁–C₃perfluoroalkylthio, —OCHF₂, —CN, —COOH, —CH₂CO₂H, —C(O)CH₃, —CO₂R₇,—C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂; or (b) the moiety X—R₆; R₆ isC₁–C₈ alkyl, C₁–C₈ alkenyl, C₁–C₈ alkynyl, C₃–C₆ cycloalkyl, —CH₂—C₃–C₆cycloalkyl, heteroaryl, phenyl, aryl-alkyl where the alkyl chain isC₁–C₈, CH₂CH₂-phenyl, or CH₂CH₂-napthyl, wherein the alkyl, alkenyl,alkynyl, cycloalkyl, heteroaryl, phenyl, and napthyl groups areoptionally substituted by from 1 to 3 groups selected from halogen,C₁–C₃ alkyl, C₁–C₃ perfluoroalkyl, —O—C₁–C₃ perfluoroalkyl, —S—C₁–C₃perfluoroalkyl, C₁–C₃ alkoxy, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —S(O)₂CH₃,—OH, —NH₂, or —NO₂; and R₇ is C₁–C₆ alkyl, C₃–C₆ cycloalkyl, —CH₂—C₃–C₆cycloalkyl, or aryl-alkyl where the alkyl chain is C₁—C₈; or apharmaceutically acceptable salt or ester form thereof.
 2. A compound offormula (II):

wherein: R₄ is hydrogen, halogen, C₁–C₆ alkyl, C₁–C₃ haloalkyl, C₁–C₃perfluoroalkyl, —O—C₁–C₃ perfluoroalkyl, —S—C₁–C₃ perfluoroalkyl, C₁–C₃alkoxy, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —S(O)₂CH₃, —OH, —NH₂, or —NO₂; R₅is C₁–C₈ alkyl, C₁–C₃ perfluoroalkyl, —CH₂—C₃–C₆ cycloalkyl,—CH₂-heteroaryl, or aryl-alkyl where the alkyl chain is C₁–C₈, whereinthe rings of the cycloalkyl, heteroaryl, and aryl groups are optionallysubstituted by from 1 to 5 groups selected from halogen, C₁–C₃ alkyl,C₁–C₃ perfluoroalkyl, —O—C₁–C₃ perfluoroalkyl, —S—C₁–C₃ perfluoroalkyl,C₁–C₃ alkoxy, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇, —S(O)₂CH₃, —OH, —NH₂, or—NO₂; R₂ is hydrogen, C₁–C₆ alkyl, or C₁–C₃ perfluoroalkyl, wherein thealkyl group is optionally substituted by halogen, —CN, C₁–C₆ alkoxy,—COOH, —CH₂CO₂H, —C(O)CH₃, —CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or—NO₂; R₃ is hydrogen, halogen, C₁–C₈ alkyl, C₁–C₈ alkenyl, C₁–C₈alkynyl, C₃–C₆ cycloalkyl, —CH₂—C₃–C₆ cycloalkyl, heteroaryl, or phenyl,wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and phenylgroups are optionally substituted by from 1 to 3 groups selected fromhalogen, C₁–C₃ alkyl, C₁–C₃ perfluoroalkyl, —S—C₁–C₃ perfluoroalkyl,—S—C₁–C₃ perfluoroalkyl, C₁–C₃ alkoxy, —OCHF₂, —CN, —C(O)CH₃, —CO₂R₇,—S(O)₂CH₃, —OH, —NH₂, or —NO₂; R₇ is C₁–C₆ alkyl, C₃–C₆ cycloalkyl,—CH₂—C₃–C₆ cycloalkyl, or aryl-alkyl where the alkyl chain is C₁–C₈; ora pharmaceutically acceptable salt or ester form thereof.
 3. Thecompound of claim 1 which is(1-{4-[(4-cyanobenzyl)oxy]phenyl}-1H-indol-3-yl)(oxo)acetic acid, or apharmaceutically acceptable salt or ester form thereof.
 4. The compoundof claim 1 which is{1-[4-(3-methoxy-benzyloxy)-phenyl]1H-indol-3-yl}-oxo-acetic acid, or apharmaceutically acceptable salt or ester form thereof.
 5. The compoundof claim 1 which is{1-[4-(3-chloro-benzyloxy)-phenyl]1H-indol-3-yl}-oxo-acetic acid, or apharmaceutically acceptable salt or ester form thereof.
 6. The compoundof claim 1 which is{1-[4-(4-cyanobenzyloxy)-phenyl]-5-fluoro-1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 7.The compound of claim 1 which is{1-[4-(3,5-dimethoxy-benzyloxy)-phenyl]-5-fluoro-1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 8.The compound of claim 1 which is{1-[4-(3-chloro-benzyloxy)-phenyl]-5-methyl-1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 9.The compound which is{1-[4-(4-tert-butylbenzyloxy)-phenyl]-5-methyl-1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 10.The compound of claim 1 which is{1-[4-(2,4-dichlorobenzyloxy)-phenyl]-5-methyl-1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 11.The compound of claim 1 which is{5-Chloro-1-[3-(4-cyanobenzyloxy)-phenyl]1H-indol-3-yl}-oxo-acetic acid,or a pharmaceutically acceptable salt or ester form thereof.
 12. Thecompound of claim 1 which is {5-Chloro-1-[3-(3,5-dimethoxybenzyloxy)-phenyl]1H-indol-3-yl}-oxo-acetic acid, or a pharmaceuticallyacceptable salt or ester form thereof.
 13. The compound of claim 1 whichis{1-[4-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzyloxy)-phenyl]1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 14.The compound which is{1-[4-(4-[1,2,3]thiadiazol-4-yl-benzyloxy)-phenyl]-1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 15.The compound of claim 1 which is{1-[4-(2,6-dichloro-pyridin-4-ylmethoxy)-phenyl]1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 16.The compound of claim 1 which[1-(4-{[5-(ethoxycarbonyl)-2-furyl]methoxy}phenyl)-5-fluoro-1H-indol-3-yl](oxo)aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 17.The compound of claim 1 which is{1-[4-(2,6-dichloropyridin-4-ylmethoxy)-phenyl]-5-methyl-1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 18.The compound of claim 1 which is{5-Chloro-1-[3-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzyloxy)-phenyl]1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 19.The compound of claim 1 which is[5-chloro-1-(3-{[5-(ethoxycarbonyl)-2-furyl]methoxy}phenyl)-1H-indol-3-yl](oxo)aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 20.The compound which is{5-Chloro-1-[3-(4-[1,2,3]thiadiazol-4-yl-benzyloxy)-phenyl]1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 21.The compound of claim 1 which is{5-Chloro-1-[3-(2,6-dichloro-pyridin-4-ylmethoxy)-phenyl]1H-indol-3-yl}-oxo-aceticacid, or a pharmaceutically acceptable salt or ester form thereof. 22.The compound of claim 1 which is[1,5-bis-(4-trifluoromethoxy-phenyl)-1H-indol-3-yl]-oxo-acetic acid, ora pharmaceutically acceptable salt or ester form thereof.
 23. Apharmaceutical composition comprising a compound of claim 1 and apharmaceutical carrier.
 24. A method for the treatment of thrombosis orfibrinolytic impairment in a mammal, the method comprising administeringto a mammal in need thereof a pharmaceutically effective amount of acompound of claim
 1. 25. A method of claim 24 wherein the thrombosis orfibrinolytic impairment is associated with formation of atheroscleroticplaques, venous and arterial thrombosis, myocardial ischemia, atrialfibrillation, deep vein thrombosis, coagulation syndromes, pulmonaryfibrosis, cerebral thrombosis, thromboembolic complications of surgeryor peripheral arterial occlusion.
 26. A method for the treatment ofperipheral arterial disease in a mammal, comprising administering to amammal in need thereof a pharmaceutically effective amount of a compoundof claim
 1. 27. A method for the treatment of stroke associated with orresulting from atrial fibrillation in a mammal, comprising administeringto a mammal in need thereof a pharmaceutically effective amount of acompound of claim
 1. 28. A method for the treatment of deep veinthrombosis in a mammal, comprising administering to a mammal in needthereof a pharmaceutically effective amount of a compound of claim 1.29. A method for the treatment of myocardial ischemia in a mammal,comprising administering to a mammal in need thereof a pharmaceuticallyeffective amount of a compound of claim
 1. 30. A method for thetreatment of a cardiovascular disease caused by noninsulin dependentdiabetes mellitus in a mammal, comprising administering to a mammal inneed thereof a pharmaceutically effective amount of a compound ofclaim
 1. 31. A method for the treatment of the formation ofatherosclerotic plaques in a mammal, comprising administering to amammal in need thereof a pharmaceutically effective amount of a compoundof claim
 1. 32. A method for the treatment of chronic obstructivepulmonary disease in a mammal, comprising administering to a mammal inneed thereof a pharmaceutically effective amount of a compound ofclaim
 1. 33. A method for the treatment of renal fibrosis in a mammal,comprising administering to a mammal in need thereof a pharmaceuticallyeffective amount of a compound of claim
 1. 34. A method for thetreatment of polycystic oyary syndrome in a mammal, comprisingadministering to a mammal in need thereof a pharmaceutically effectiveamount of a compound of claim
 1. 35. A method for the treatment ofAlzheimer's disease in a mammal, comprising administering to a mammal inneed thereof a pharmaceutically effective amount of a compound ofclaim
 1. 36. A method for the treatment of breast or ovarian cancer in amammal, comprising administering to a mammal in need thereof apharmaceutically effective amount of a compound of claim
 1. 37. Acompound of claim 1 wherein: R₅ is arylalkyl where the alkyl chain isC₁—C₈, wherein the aryl group is optionally substituted by from 1 to 5groups selected from halogen, C₁—C₃ alkyl, C₁—C₃ haloalkyl, C₁—C₃perfluoroalkyl, C₁—C₃ alkoxy, C₁—C₃ perfluoroalkoxy, C₁—C₃ alkylthio,C₁—C₃ perfluoroalkylthio, —OCHF₂, —CN, —COOH, —CH₂CO₂H, —C(O)CH₃,—CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂; or a pharmaceuticallyacceptable salt or ester form thereof.
 38. compound of claim 1 wherein:R₅ is C₃—C₆ cycloalkyl, —CH₂—C₃-C₆ cycloalkyl, heteroaryl,—CH₂-heteroaryl, or arylalkyl where the alkyl chain is C₁—C₈, whereinthe rings of the cycloalkyl, heteroaryl, and aryl groups are optionallysubstituted by from 1 to 5 groups selected from halogen, C₁—C₃ alkyl,C₁—C₃ haloalkyl, C₁—C₃ perfluoroalkyl, C₁—C₃ perfluoroalkoxy, C₁—C₃alkylthio, C₁—C₃ perfluoroalkylthio, —OCHF₂, —CN, —COOH, —CH₂CO₂H,—C(O)CH₃, —CO₂R₇, —C(O)NH₂, —S(O)₂CH₃, —OH, —NH₂, or —NO₂; or apharmaceutically acceptable salt or ester form thereof.
 39. A compoundof claim 2 wherein: R₅ is aryl-alkyl where the alkyl chain is C₁—C₈,wherein the aryl group is optionally substituted by from 1 to 5 groupsselected from halogen, C₁—C₃ alkyl, C₁—C₃ perfluroalkyl, —O—C₁—C₃perfluoroalkyl, S—C₁—C₃ perfluoroalkyl, C₁—C₃ alkoxy, —OCHF₂, —CN,—C(O)CH₃, —CO₂R₇, —S(O)₂CH₃, —OH, —NH₂, or —NO₂; or a pharmaceuticallyacceptable salt or ester form thereof.
 40. A compound of claim 2wherein: R₅ is —CH₂—C₃—C₆ cycloalkyl, —CH₂-heteroaryl, or aryl-alkylwhere the alkyl chain is C₁—C₈, wherein the rings of the cycloalkyl,heteroaryl, and aryl groups are optionally substituted by from 1 to 5groups selected from halogen, C₁—C₃ alkyl, C₁—C₃ perfluoroalkyl,—O—C₁—C₃ perfluoroalkyl, S—C₁—C₃ perfluoroalkyl, C₁—C₃ alkoxy, —OCHF₂,—CN, —C(O)CH₃, —CO₂R₇, —S(O)₂CH₃, —OH, —NH₂,or —NO₂; or apharmaceutically acceptable salt or ester form thereof.